Baldi, GG, Giani, C, Ljevar, S, Denu, RA, Napolitano, A, Han, I, Brunello, A, Bhadri, V, Sebio, A, Andelkovic, V, Campos, F, Scanferla, R, Abreu, MH, Desar, IME, Ogura, K, Wong, DD, Bae, S, Bakhshi, S, Lefler, DS, Marquina, G, Mazzocca, A, Nakazawa, MS, Thway, K, Kim, HS, Chiusole, B, Connolly, EA, Terés, R, Antonescu, C, Bellan, E, Bovee, JVMG, Davis, JL, Tos, APD, Di Blasi, E, Lazar, AJ, Sbaraglia, M, Schaefer, IM, Taverna, S, Gronchi, A, Miceli, R, Chen, TW, Stacchiotti, S. Pleomorphic rhabdomyosarcoma, outcomes of patients with advanced disease treated with systemic agents: Retrospective study from the global pushing ultra-rare sarcomas towards hope (PUSH) consortium. EUROPEAN JOURNAL OF CANCER. 2026; 238DOI:10.1016/j.ejca.2026.116666. PMID:41819027. IF:7.100(Q1/2D).

Baturone, A, Serrano, FJ, Camblor, LA, Alonso, M, García, F, Rodríguez, M, Marquina, R, Egaña, JM, Lozano, C, Landaluce, M, Garzón, N, Miralles, M, Fité, J, Escudero, JR, Olmos, D, Gomez-Palonés, F, Ligero, JM, Martín, A. Biosynthetic Prosthesis Omniflow II in Chronic-Limb Threatening Ischemia: Results of the Multicenter National Registry Omni-Femoropopliteal. ANNALS OF VASCULAR SURGERY. 2026; 126DOI:10.1016/j.avsg.2025.12.037. PMID:41544849. IF:1.600(Q2/5D).

Vergouwen, MDI, Ramos-Pachon, A, Terecoasa, EO, Willett, N, Cuadrado-Godia, E, Gaberel, T, Gizewski, ER, Helbok, R, Ho, LA, Hugelshofer, M, Korja, M, Meling, TR, Psychogios, MN, Rinkel, GJE, Taschner, CA, Vajkoczy, P, Etminan, N. European Stroke Organisation (ESO), European Association of Neurosurgical Societies (EANS) and European Society for Minimally Invasive Neurological Therapy (ESMINT) guideline on aneurysmal subarachnoid haemorrhage. European Stroke Journal. 2026; 11(5)DOI:10.1093/esj/aakag043. PMID:42095754. IF:4.500(Q1/2D).

Volta-Durán, E, Alba-Castellon, L, Arena, LA, Sánchez, JM, Casanova, I, Mangues, R, Villaverde, A, Vázquez, E, Unzueta, U. KDEL-mediated modulation of intracellular trafficking in cell-targeted protein drugs. EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS. 2026; 222DOI:10.1016/j.ejpb.2026.115020. PMID:41690333. IF:4.300(Q1/2D).

Cortés-Vicente, E, Guerrero, A, Díaz, C, Martínez, E, Toja-Camba, FJ, Abad, MR, Serra, JM, Trillo, JL, Machín, CM, Gil, A. Assessing the Value Contribution of Vyvgart® (Efgartigimod Alfa) in the Treatment of Generalized Myasthenia Gravis with Acetylcholine Receptor Antibody in Spain Through Multi-criteria Decision Analysis (Jan, 10.1007/s12325-026-03490-x, 2026). ADVANCES IN THERAPY. 2026; 43(5)DOI:10.1007/s12325-026-03532-4. PMID:41817916. IF:4.000(Q1/3D).

Behrens, GMN, Assoumou, L, Liegeon, G, Antinori, A, Micán, R, Genderini, FG, Post, FA, Rockstroh, JK, Hamzah, L, Domingo, P, Curran, A, Laguno, M, Fletcher, C, Moody, J, Pozniak, A. Integrase versus protease inhibitor therapy in advanced HIV disease (LAPTOP): a multicountry, randomised, open-label, non-inferiority trial. LANCET INFECTIOUS DISEASES. 2026; 26(5)DOI:10.1016/S1473-3099(25)00681-4. PMID:41344354. IF:31.000(Q1/1D).

Novello, S, Rabinovich, NM, Shih, JY, Pelizzari, G, Stevenson, J, Majem, M, Ferreira, CG, Petty, WJ, Arriola, E, Castagneris, N, De Castro, J, Morbeck, I, Bauman, J, Toschi, L, Zer, A, Metro, G, Kalmadi, S, Martinez, AA, Al Husaini, H, Meloni, AR, Nduka, C, Ardito-Abraham, C, Xia, CH, Awad, MM. Sotorasib in Advanced KRAS G12C-Mutated NSCLC Results From the Global Expanded Access Program Including Patients With Poor Performance Status and a History of CNS Metastases. Jto Clinical And Research Reports. 2026; 7(5)DOI:10.1016/j.jtocrr.2026.100974. PMID:42006282. IF:(Q/D).

Espinosa, E, Berciano-Guerrero, MA, Muñoz-Couselo, E, Puértolas, T, Manzano, JL, Soria, A, De Miguel, PA, Crespo, G, Sanz, LG, Cerezuela-Fuentes, P, de la Rosa, CA, Majem, M, Castaño, AG, Berrocal, A, Arroyo, FRG, de la Borbolla, MR, Bellido, L, Martínez, JM, Fernández, LA, Carnicero, AM, Castro, RL, Rodríguez, AB, Lecumberri, MJ, Guzmán, JCV, Balea, BC, Rodríguez, JF, Bautista, JV, Pérez, VN, Mujika, K, Subias, MC, Hernández, B, Algarra, SM, Márquez-Rodas, I. Response rate and long-term survival in patients with advanced melanoma: data from the prospective cohort study gem-1801. Clinical & Translational Oncology. 2026; 28(5)DOI:10.1007/s12094-025-04098-3. PMID:41313559. IF:2.500(Q3/6D).